ArticleOphthalmology2022

Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.

Sharon F Freedman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.